Literature DB >> 9859881

Two- to six-year controlled-trial stuttering outcomes for children and adolescents.

K Hancock1, A Craig, C McCready, A McCaul, D Costello, K Campbell, G Gilmore.   

Abstract

This research is a long-term follow-up of a previously published, controlled trial on the effectiveness of 3 stuttering treatments (intensive smooth speech, parent-home smooth speech, and intensive electromyography feedback) for children and adolescents, aged 11 to 18 years, who stutter. The previous controlled trial showed all 3 treatments to be effective compared to nontreatment after 12 months. This paper reports on the treatment effectiveness after an average of 4 years post-treatment. Results demonstrate that treatment gains were maintained in the long term, with rates of stuttering similar to the 1-year postoutcomes. There were no significant differences among the 3 treatments in long-term effectiveness. This controlled study substantiates the claim that the treatments investigated will more than likely have substantial long-term benefits for the fluency and personality of children and adolescents who stutter.

Entities:  

Mesh:

Year:  1998        PMID: 9859881     DOI: 10.1044/jslhr.4106.1242

Source DB:  PubMed          Journal:  J Speech Lang Hear Res        ISSN: 1092-4388            Impact factor:   2.297


  3 in total

Review 1.  Stuttering: an update for physicians.

Authors:  D Costa; R Kroll
Journal:  CMAJ       Date:  2000-06-27       Impact factor: 8.262

Review 2.  The state of the art in non-pharmacological interventions for developmental stuttering. Part 1: a systematic review of effectiveness.

Authors:  Susan Baxter; Maxine Johnson; Lindsay Blank; Anna Cantrell; Shelagh Brumfitt; Pam Enderby; Elizabeth Goyder
Journal:  Int J Lang Commun Disord       Date:  2015-06-30       Impact factor: 3.020

3.  Multimodal explainable AI predicts upcoming speech behavior in adults who stutter.

Authors:  Arun Das; Jeffrey Mock; Farzan Irani; Yufei Huang; Peyman Najafirad; Edward Golob
Journal:  Front Neurosci       Date:  2022-08-01       Impact factor: 5.152

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.